NXT-ID, Inc. (Nasdaq:NXTD)Rolls out NFC Enabled Wocket Smart Wallets for 2016

Melbourne FL, January 25, 2016 -- NXT-ID, Inc. (NASDAQ: NXTD) ("NXT-ID" or the "Company"), a company focused on the growing mobile commerce market, announces that effective January 2016, all Wockets sold will be enabled with NFC (Near Field Communication) payment technology.

As new partnerships with financial institutions are completed, Wocket owners will be notified when they can make NFC payment transactions.This will require a software upgrade through the Wocket app.Gino Pereira, CEO of NXT-ID explains “The next generation Wockets are NFC enabled for payments like Apple Pay or Google Pay. It works as they do when you tap your Wocket to a terminal and it takes your payment. In 2016 we envision several product extensions for Wocket including NFC only Wockets and a new smartcard and app product all at different price points for various customer needs and preferences.”

WorldVenturesAnnounces New DreamTrips SmartCard Developed by NXT-ID (Nasdaq:$NXTD) to Over 22,000 Members at Annual Conference

Melbourne FL, January 19, 2016 -- NXT-ID, Inc. (NASDAQ: NXTD)("NXT-ID" or the "Company"), a company focused on the growing mobile commerce market, reports the new smart card being developed for WorldVentures Vacation Club Members was introduced to an enthusiastic audience at their annual UNITED conference, held in Orlando, Fla. Jan.15-17^th.

On Jan. 4, WorldVentures and NXT-ID, Inc. announced a strategic alliance to develop a proprietary new wireless smart card for its Members, based on NXT-ID’s Wocket® smart wallet technology.

According to WorldVentures, “Over 22,000 Independent Representatives came together to celebrate past successes, look ahead to the next decade with innovative new technologies and travel products, and give back to the Orlando community.”

NTT positioned as a challenger in the Gartner Magic Quadrant for Managed Security Services, Worldwide

Evaluation based on completeness of vision and ability to execute

Fleet, Hants, UK – 12 January 2016– NTT (NYSE: NTT) announced that Gartner, Inc., a leading IT research and advisory firm, has positioned NTT in the “Challengers” Quadrant of the 2015 Magic Quadrant for Managed Security Services, Worldwide[1].

NTT and its operating companies offer a wide range of managed security services (MSS) to large and mid-sized enterprises. The company has been expanding its capabilities, solutions, and global reach in managed security services through a series of strategic acquisitions, consolidations and internal development in recent years.

Gartner defines managed security services as “the remote monitoring or management of IT security functions delivered via shared services from remote security operations centers (SOCs), not through personnel on-site.” Gartner writes, “This Magic Quadrant evaluates services for monitored/managed firewall and intrusion detection and prevention functions, as well as log analysis and reporting services. These functions make up the core of MSS procurements.”

Aethlon Medical’s (Nasdaq: AEMD) ExosomeSciences to Participate in Clinical Research Study To Diagnose Chronic Traumatic Encephalopathy (CTE)

SAN DIEGO, CA, January 12, 2016 – Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical, Inc. (Nasdaq:AEMD), announced today that it has agreed to participate in a clinical research study to establish methods for detecting and diagnosing chronic traumatic encephalopathy (CTE) during life as well as examining risk factors for CTE. CTE is a disease of the brain often found in athletes, military veterans, and others with a history of repetitive head impacts. At present, CTE can only be definitively diagnosed through post-mortem examination of brain tissue.

The research study will be conducted under a $16 million grant that the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) has awarded to researchers from Boston University, the Cleveland Clinic, Banner Alzheimer’s Institute and Brigham and Women’s Hospital in Boston.  Overall, the project will involve a group of approximately 50 investigators, representing 17 research institutions.  Exosome Sciences has agreed to test an exosomal tau biomarker (TauSome™) that it has been advancing as a blood-based candidate to diagnose CTE.